{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 25,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide compares the library against a benchmark (IMAB027) in terms of reactivity and cytotoxicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/20",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.04,
        "y": 0.185
      },
      "kind": "callout",
      "text": "Bispecific antibodies retain high CLDN6 specificity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9eddf13b-5063-4024-a096-e6229d54e90f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.52,
        "y": 0.185
      },
      "kind": "callout",
      "text": "Bispecifics induce robust T-cell dependent cytotoxicity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0db3e91-5754-4952-8c77-c0359412f057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.52,
        "y": 0.32
      },
      "kind": "chart",
      "text": "T-cell Dependent Cytotoxicity",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa311105-ade9-4b3b-9975-facf9ae74584",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "chart",
      "text": "CLDN9 Reactivity",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edf2d351-7fce-4a93-8430-deff391b9432",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.52,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dce63d43-3d06-4790-bd09-d38a169edd12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "CLDN6xCD3 Bispecific Antibody Library",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92c5a661-58e6-449d-88ea-ce90564126cd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "49bdab9d-f894-43d5-bc17-ae9acbbc7766",
      "evidence": "chart/line: T-cell Dependent Cytotoxicity",
      "confidence": 0.7
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "62b0791e-b273-4715-b99e-857240cef590",
      "evidence": "callout/primary: Bispecifics induce robust T-cell dependent cytotoxicity",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f563f0a-bba6-40be-8cea-242e5c29e44d",
      "evidence": "Slides 11-24 outline the potential of ONA-XR and CLDN6xCD3 Bispecific Antibody Program",
      "position": 0,
      "objective": "Highlight the benefits of investment in Context Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}